Learn More
A phase III clinical trial to test the effectiveness of the HIV microbicide Ushercell was recently stopped because interim analysis indicated that the rate of infection with HIV in women using the microbicide was higher than the rate of infection in those using the placebo. Ushercell, which was being developed by the nonprofit reproductive health(More)
Improving the translation of basic research into the clinic is fast becoming a priority not just in the US but also in Europe. In the US, one of the biggest initiatives to enhance translational research is sponsored by the NIH through its Clinical and Translational Science Awards (CTSAs). The first CTSAs were awarded to 12 institutions in October last year,(More)
The results of an early-stage clinical trial have brought closer the prospect of a vaccine to help protect infants and children from becoming infected with a parasite that causes the most deadly form of malaria, a disease that, according to the WHO, kills more than one million people every year (1). Although the primary goal of the phase I/IIb clinical(More)
The Journal of Clinical Investigation http://www.jci.org Volume 118 Number 3 March 2008 825 The comeback kid: TYSABRI now FDA approved for Crohn disease The US FDA recently approved the monoclonal antibody TYSABRI (natalizumab) for use in the treatment of adults with moderately to severely active Crohn disease (CD) who do not respond to, or do not tolerate,(More)
Research into the pathogenesis, prevention, and control of infectious and parasitic diseases remains a global priority, as these scourges continue to be a substantial cause of mortality and morbidity. The plethora of molecular tools that are now readily available has facilitated a genome-wide approach to studying the pathogenesis of such diseases, with(More)
Avastin, a VEGF-specific monoclonal antibody originally designed to inhibit angiogenesis (Figure 1), has recently made the headlines with both positive and negative clinical progress. At the start of May, it was approved by the FDA for use as a treatment for glioblastoma that has recurred after standard therapies, but in April a clinical trial assessing the(More)